Soy isoflavone supplementation increases equol-producing capability in postmenopausal women with osteopenia

Main Article Content

Elly Herwana
Rianto Setiabudy
Sidartawan Soegondo
Ali Baziad
Adi Hidayat

Abstract

Background
Isoflavone containing soy protein has been associated with beneficial health effects. Equol, a gut bacterial metabolite of the isoflavone daidzein, has been hypothesized to be the cause of the effectiveness of isoflavones. The objective of this study was to evaluate the effect of 100 mg/day soy isoflavone supplementation for 3 months on the ability to produce equol in postmenopausal women with osteopenia.

Method
A pre-post experimental study was conducted to assess the effects of 100 mg/day soy isoflavone supplementation on equol production capability and the proportion of equol producers to non-equol producers in postmenopausal women with osteopenia. A total of 39 subjects received 1 supplement tablet containing 100 mg soy isoflavones (genistein, daidzein) for 3 months. Determination of serum genistein, daidzein, and equol concentrations was performed twice at baseline and at 3 months post-supplementation using high-performance liquid chromatography mass spectrophotometry (HPLC-MS). Equol producer status was determined by the detection of a serum equol concentration of 5 µg/L.

Results
Mean genistein and daidzein concentrations at baseline were 86.2 ± 68.4 ìg/L and 16.7 ± 18.6 ìg/L, respectively. The proportion of equol producers was 69.2%. After 3 months of soy isoflavone supplementation the serum concentrations of genistein and daidzein significantly increased to 161.0 ± 5.8 ìg/L (p=0.000) and 49.9 ± 40.4 ìg/L (p=0.000), respectively, and the proportion of equol producers also significantly increased (100.0%).

Conclusion
Soy isoflavone supplementation was capable of increasing the serum concentrations of isoflavones (genistein and daidzein) and the equol-producing capacity of postmenopausal women with osteopenia.

Article Details

How to Cite
Herwana, E., Setiabudy, R., Soegondo, S., Baziad, A., & Hidayat, A. (2012). Soy isoflavone supplementation increases equol-producing capability in postmenopausal women with osteopenia. Universa Medicina, 31(2), 120–130. https://doi.org/10.18051/UnivMed.2012.v31.120-130
Section
Review Article

References

Nelson HD. Menopause. The Lancet 2008;371: 760-70.

Raisz LG. Pathogenesis of osteoporosis: concepts, conflict, and prospects. J Clin Invest 2005;115: 3318-25.

Finkelstein JS, Brockwell SE, Mehta V, GreendaleGA, Sowers MR, Ettinger B, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008;93:861-8.

Deroo BJ, KorachKS. Estrogen receptor and human disease. J Clin Invest 2006;116:561-70.

Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006;116:1186-94.

Gustafsson JA. ERâ scientific visions translate to clinical uses. Climacteric 2006;9:156-60.

Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F,et al. European guidance for diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 2008;19:399-428.

de Villiers T. The role of menopausal hormone therapy in osteoporosis. Climacteric 2007;10:71-3.

Barlow DH. Osteoporosis guidelines. Climacteric 2007;10(Suppl 2):79-82.

Jordan N, Barry M, Murphy E. Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clin Invest Aging 2006;1:377-87.

Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Annals Intern Med 2002;137:805-13.

Chanteranne B, Branca F, Kaardinal A, Wahala K, Braesco V, Ladroite P, et al. Food matrix and isoflavones bioavailability in early post menopausal women: a European clinical study. Clin Interv Aging 2008;3:711-8.

Setchell KDR, Lydeking-Olsen E. Dietary phytoestrogen and their effect on bone: evidence from in-vitro and in-vivo, human observational, and dietary intervention studies. Am J Clin Nutr 2003;78:593S-609S.

Vincent A, Fitzpatrick LA. Soy isoflavones: are they useful in menopause? Mayo Clin Proc 2000; 75:1174-83.

Wood CE, Appt SE, Clarkson TB, Franke AA, Lees CJ, Doerge DR, et al. Effect of high-dose soy isoflavones and equol on reproductive tissues in female cynomolgus monkeys. Biol Reprod 2006;75:477-86.

Setchell KDR. Soy isoflafone-benefit and risk from narure’s selective estrogen receptor modulators (SERMs). J Am Coll Nutr 2001;20: 354S-62S.

Mathey J, Mardon J, Fokialakis N, Puel C, Kati-Coulibaly S, Mitakou S, et al. Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol. Osteoporos Int 2007;18:671-9.

Fujioka M, Uehara M, Wu J, Adlercreutz H, Suzuki K, Kanasawa K, et al. Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice. J Nutr 2004;134:2623-7.

Setchell KDR, Brown NM, Olsen EL. The clinical importance of the metabolite equol –a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-85.

Vedrine N, Mathey J, Morand C, Brandolini M, Davicco MJ, Guy L, et al. One-month exposure to soy isoflavones did not induce the ability to produce equol in postmenopausal women. Eur J Clin Nutr 2006;60:1039-45.

Bolca S, Possemiers S, Herregat A, Huybrechts I, Heyerick A, De Vriese S, et al. Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr 2007;137:2242-6.

Decroos K, Eeckhaut E, Possemiers S, Verstraete W. Administration of equol-producing bacteria alters the equol production status in the simulator of the gastrointestinal microbial ecosystem (SHIME). J Nutr 2006;136:946-52.

Setchell KDR, Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr 2006;136:2188-93.

Frankenfeld CL, Atkinson C, Thomas WK, Gonzales A, Jokela T, Wahala K, et al. High concordance of daidzein metabolizing phenotypes in individuals measured 1 to 3 years apart. Br J Nutr 2005;94:873-6.

Mascarinec G, Yamakawa R, Hebshi S, Franke AA. Urinary isoflavonoid excretion and soy consumption in three generation of Japanese women in Hawaii. Eur J Clin Nutr 2007;61:255-61.

Lampe JW, Chang JL. Interindividual differences in phytochemical metabolism and disposition. Semin Cancer Biol 2007;17:347-53.

Vergne S, Sauvant P, Lamothe V, Chantre P, Asselineau J, Perez P, et al. Influence of ethnic origin (Asian vs. Caucasian) and background diet on the bioavailability of dietary isoflavones. Br J Nutr 2009;102:1642-53.

Meiyanti. Epidemiology of osteoporosis in postmenopausal women aged 47 to 70 years. Univ Med 2010;29:169-76.

Lee KJ, Row KH, Jun IC. Preparative separation of isoflavones from Korean soy bean be HPLC. Asian J Scien Res 2008;3:288-92.

Huang Y, Cao S, Nagamani M, Anderson KE, Grady JJ, Lu LJW. Decreased circulating levels of tumor necrosis factor-a in postmenopausal women during consumption of soy-containing isoflavones. J Clin Endocrinol Metab 2005;90: 3956–62.

Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 2006;55:1–12.

Lampe JW. Is equol the key to the efficacy of soy foods? Am J Clin Nutr 2009;89 Suppl:S1664-7.

Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, et al. Comparisons of percent equol producer between prostate cancer patients and controls: case controlled studies of isoflavones in Japanese, Korean and American residents. Jpn Clin Oncol 2004:34:86-9.

Liu B, Qin L, Liu A, Uchiyama S, Ueno T, Li X, et al. Prevalence of equol-producer phenotype and its relationship with dietary isoflavone and serum lipids in healthy Chinese adult. J Epidemiol 2010;20:377-84.

Pusparini. Pengaruh suplementasi isoflavon kedelai terhadap penanda fungsi endotel pada perempuan pascamenopause (disertasi). Jakarta: Universitas Indonesia; 2011.